Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome

Clin Endocrinol (Oxf). 2010 Mar;72(3):423-5. doi: 10.1111/j.1365-2265.2009.03643.x. Epub 2009 May 29.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Drug Therapy, Combination
  • Female
  • Gastric Inhibitory Polypeptide / blood*
  • Glucagon-Like Peptide 1 / blood*
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Metformin / pharmacology
  • Metformin / therapeutic use*
  • Obesity / complications
  • Obesity / drug therapy
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Polycystic Ovary Syndrome / blood
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / drug therapy*
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Rimonabant

Substances

  • Hypoglycemic Agents
  • Piperidines
  • Pyrazoles
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1
  • Metformin
  • Rimonabant